MDI and DPI Drug Products
...The guidance sets forth information that should be provided to ensure continuing drug.....manufacturing, processing, packaging, controls, stability testing, or labeling operations.....stability test storage conditions. Additional studies should be performed to characterize..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=100)

þÿ
...18 The applicant and/or drug product manufacturer must establish the reliability of the.....process test and the drug substance test, the acceptance criterion for the in-process test.....should explain the scientific reasons why a stability indicating procedure is not viable..
http://www.fda.gov/cder/guidance/3969DFT.pdf (score=81)

þÿ
...18 The applicant and/or drug product manufacturer must establish the reliability of the.....process test and the drug substance test, the acceptance criterion for the in-process test.....should explain the scientific reasons why a stability indicating procedure is not viable..
http://www.fda.gov/OHRMS/DOCKETS/98fr/2003d-0571-gdl0001.pdf (score=78)

stability guidance -draft
...Significant change for a drug product at the accelerated stability condition and the.....In general, moderate and excellent stability mean little or no change in product test results for.....The stability of the drug product after reconstituting or diluting according to labeling..
http://www.fda.gov/cder/guidance/1707dft.pdf (score=69)

PET Drug Products … Current Good Manufacturing Practice (CGMP)
...ensure that each batch of PET drug product meets its established acceptance criteria, 1201.....stability parameters include radiochemical identity and purity, appearance, pH, stabilizer.....of false-positive results arises in the sampling and transfer of the test aliquot from the..
http://www.fda.gov/cder/guidance/4259dft.pdf (score=66)

Packaging
...It should provide an adequate seal, be compatible with the drug product, and not be a source of.....This information should include the proposed market package for the product and the relevant stability and.....A further test to supplement the mouse subchronic systemic test is the procedure for eye..
http://www.fda.gov/cder/guidance/package.htm (score=64)

PET Drug Products - Current Good Manufacturing Practice (CGMP)
...Appropriate parameters should be evaluated to establish and document the stability of a PET drug product under.....The reliability of the supplier's test results can be established by conducting.....Stability testing of the PET drug product should be performed at the highest radioactive concentration, and the whole batch..
http://www.fda.gov/cder/guidance/4259dft.htm (score=63)

Guidance for Industry
...ensuring that the drug product provided to the patient has the appropriate identity, strength.....and approved lot, we recommend that the manufacturer test the combined product and approve.....provided that they meet appropriate standards or specifications as demonstrated by..
http://www.fda.gov/OHRMS/DOCKETS/98fr/03d-0165-gdl0001.pdf (score=62)

Validation of Chromatographic Methods
...Solution stability of the drug substance or drug product after preparation..according to the test method should be evaluated.....with the regulatory impurities method relating to release and stability of..both drug substance and drug product.Detection limit is.....The objective of a test method is to generate reliable and accurate data regardless of..
http://www.fda.gov/cder/guidance/cmc3.pdf (score=61)

Q1B Photostability Testing of New Drug Substances and Products
...The extent of drug product testing should be established by assessing whether or not acceptable.....The ICH Harmonized Tripartite Guideline on Stability Testing of New Drug Substances and.....Care should be taken to ensure that the physical characteristics of the samples under test..
http://www.fda.gov/cder/guidance/1318.htm (score=56)

HUMAN DRUG CGMP NOTES December 1998
...84, Testing and approval or rejection of components, drug product containers, and closures.....As of May, 1998, TOC is the official organic impurities test for USP pharmaceutical.....84, Testing and approval or rejection of components, drug product containers, and closures..
http://www.fda.gov/cder/hdn/cnotesd8.htm (score=54)

/a//content.14388
...Mixing, granulating, milling, molding, of components, drug product containers, formulating.....The accuracy, sensitivity, specificity, test the product for the presence of the.....whether they use terminal sterilization, three initial batches in the stability.. Sampling..
http://www.fda.gov/cder/dmpq/fr5396.pdf (score=53)

Substance
...individual batches of the drug substance used in animal and clinical testing, Drug.....relation to the amount of crude product, whether it is filtered while hot, whether a.....intermediate(s) or steps in the process to test, and the kind of testing required, are the..
http://www.fda.gov/cder/guidance/drugsub.pdf (score=52)

Guidance on the Packaging of Test Batches
...For liquids, the total amount of bulk product packaged should be,at a minimum, 10 percent.....To provide information concerning the processing, packaging and labeling of test..batches for Abbreviated New Drug.....bioequivalence study and stability studies. As an example, the number of..containers which..
http://www.fda.gov/cder/mapp/5225-1.pdf (score=51)

Human Drug Notes
...65 require that equipment used in processing of a drug product be suitable for its intended use.....A practice observed during some inspections of finished drug manufacturers is the transcription of test results from the supplier's.....In the latter case, until appropriate stability data is generated, the expiration date..
http://www.fda.gov/cder/hdn/hdn1295.htm (score=46)

...The stability of a botanical drug substance or product generally should not be based entirely on the assay of the active constituents.....dissolution for solid oral dosage forms, sterility for parenterals, animal safety test for.....These regulations require documentation of the drug substance, drug product, placebo, labeling, and an..
http://www.fda.gov/cder/guidance/4592fnl.doc (score=45)

HUMAN DRUG CGMP NOTES June 1999
...The drug product lot fails the USP test requirement if any microbial growth is found and the.....Where stability information about the drug is absent, or indicates that one may expect a.....For example, the action would be a recall where a drug product labeled with the wrong..
http://www.fda.gov/cder/hdn/cnotes69.htm (score=38)

HUMAN DRUG CGMP NOTES September 1996
...What types of failures must a batch of new drug product exhibit to trigger a field alert report.....Excluding from the submission, in-process test records which show the product fails to.....Failing to submit annual reports or excluding specific lots from the stability program in..
http://www.fda.gov/cder/hdn/hdn996.htm (score=36)

HUMAN DRUG CGMP NOTES December, 1996
...Is it acceptable for a firm to use drug components, drug product containers, or drug product closures.....However, because the technology may not have been available, older applications lacking.....Concern about the potential health effects to people working with DOP test aerosols has..
http://www.fda.gov/cder/hdn/cnotesd6.htm (score=33)

Guidanc for Industry: Container and Closure Integrity Testing in Lieu of...
...testing of drugs, and provides a general indication of the information on product.....test with an appropriate container and closure integrity test in the stability protocol.....microbial barrier, and, hence, the sterility of a drug product throughout its shelf..life..
http://www.fda.gov/cber/gdlns/contain.pdf (score=29)

Las Vegas Injury Lawyer